Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 240

1.

Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment.

Moise PA, Amodio-Groton M, Rashid M, Lamp KC, Hoffman-Roberts HL, Sakoulas G, Yoon MJ, Schweitzer S, Rastogi A.

Antimicrob Agents Chemother. 2013 Mar;57(3):1192-200. doi: 10.1128/AAC.02192-12. Epub 2012 Dec 17.

2.

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fätkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE; S. aureus Endocarditis and Bacteremia Study Group.

N Engl J Med. 2006 Aug 17;355(7):653-65.

4.

Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.

Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, Rupp ME, Chambers HF, Karchmer AW, Boucher HW.

Clin Infect Dis. 2009 Mar 15;48(6):713-21. doi: 10.1086/597031.

PMID:
19207079
5.

Clinical Outcomes of Daptomycin for Vancomycin-resistant Enterococcus Bacteremia.

Moise PA, Sakoulas G, McKinnell JA, Lamp KC, DePestel DD, Yoon MJ, Reyes K, Zervos MJ.

Clin Ther. 2015 Jul 1;37(7):1443-1453.e2. doi: 10.1016/j.clinthera.2015.04.008. Epub 2015 May 15.

PMID:
25982687
6.

Efficacy and safety of daptomycin in patients with renal impairment: a multicenter retrospective analysis.

Kullar R, McClellan I, Geriak M, Sakoulas G.

Pharmacotherapy. 2014 Jun;34(6):582-9. doi: 10.1002/phar.1413. Epub 2014 Mar 21.

PMID:
24658897
7.

Daptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole.

Avery LM, Steed ME, Woodruff AE, Hasan M, Rybak MJ.

Antimicrob Agents Chemother. 2012 Nov;56(11):5990-3. doi: 10.1128/AAC.01046-12. Epub 2012 Aug 6.

8.

Clinical experience with daptomycin: bacteraemia and endocarditis.

Levine DP.

J Antimicrob Chemother. 2008 Nov;62 Suppl 3:iii35-39. doi: 10.1093/jac/dkn369. Review.

PMID:
18829724
9.

Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.

Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC.

Ann Pharmacother. 2009 Jul;43(7):1211-9. doi: 10.1345/aph.1M085. Epub 2009 Jul 7.

PMID:
19584384
11.

Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.

Bhavnani SM, Ambrose PG, Hammel JP, Rubino CM, Drusano GL.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1600-7. doi: 10.1128/AAC.02967-15.

12.

Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Kullar R, Davis SL, Kaye KS, Levine DP, Pogue JM, Rybak MJ.

Pharmacotherapy. 2013 Jan;33(1):3-10. doi: 10.1002/phar.1220.

PMID:
23307539
13.

Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study.

Murray KP, Zhao JJ, Davis SL, Kullar R, Kaye KS, Lephart P, Rybak MJ.

Clin Infect Dis. 2013 Jun;56(11):1562-9. doi: 10.1093/cid/cit112. Epub 2013 Feb 28.

PMID:
23449272
14.

Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia.

Kim SH, Kim KH, Kim HB, Kim NJ, Kim EC, Oh MD, Choe KW.

Antimicrob Agents Chemother. 2008 Jan;52(1):192-7. Epub 2007 Nov 5.

15.
16.

The efficacy of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bloodstream infection in patients with impaired renal function.

Weston A, Golan Y, Holcroft C, Snydman DR.

Clin Infect Dis. 2014 Jun;58(11):1533-9. doi: 10.1093/cid/ciu165. Epub 2014 Mar 18.

17.

Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis.

Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL.

Clin Infect Dis. 2010 Jun 15;50(12):1568-74. doi: 10.1086/652767.

PMID:
20462352
18.

Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study.

Chang FY, Peacock JE Jr, Musher DM, Triplett P, MacDonald BB, Mylotte JM, O'Donnell A, Wagener MM, Yu VL.

Medicine (Baltimore). 2003 Sep;82(5):333-9.

19.

Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin.

Ahmad NM, Rojtman AD.

Ann Pharmacother. 2010 May;44(5):918-21. doi: 10.1345/aph.1M665. Epub 2010 Mar 30.

PMID:
20354160

Supplemental Content

Support Center